TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7525185
Drug: Interferon (given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (given alone, in combination with conventional chemotherapy, or as maintenance therapy)
Study: 7525185
Drug: Myelo-ablative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myelo-ablative therapy with autologous bone marrow transplantation (with or without in vitro treatment of the marrow)
Study: 7525185
Drug: Radiolabelled monoclonal
Normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiolabelled monoclonal antibodies
Study: 7525185
Drug: Purine analogues
Normalized name: Purine analogues
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purine analogues (e.g., fludarabine)
Study: 26843588
Drug: MCCGA (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCCGA (400 mL coffee/d for 8 weeks; 420 mg CGA)
Study: 26843588
Drug: HCCGA (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCCGA (400 mL coffee/d for 8 weeks; 780 mg CGA)
Study: 24789057
Drug: DMAU 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMAU 200 mg with food
Study: 24789057
Drug: DMAU 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMAU 800 mg with food
Study: 24789057
Drug: DMAU 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMAU 800 mg fasting
Study: 22447415
Drug: Desmopressin 10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin 10, 25, 50, or 100 µg
Study: 21409314
Drug: Insulin treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin treatment (two daily injections)
Study: 19216444
Drug: 0.1% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% bupivacaine continuous drip associated to fentanyl 2 lg/mL (CP‐group)
Study: 10099740
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1.8g oral calcium daily)
Study: 1351620
Drug: Selective decontamination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective decontamination of the digestive tract (SDD) with amphotericin, colistin, and tobramycin applied to the oropharynx and enterally; all patients received intravenous cefotaxime for 72 hours.
Study: 6731167
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment locations (group C, 116 strokes)
Study: 16059622
Drug: No follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: No follow-up treatment after teriparatide
Study: 10740436
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg orally twice daily
Study: 10740436
Drug: Pivampicillin 700
Normalized name: pivampicillin
DrugBank: Pivampicillin (DB01604)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivampicillin 700 mg orally twice daily
Study: 2590265
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg ibopamine
Study: 2279257
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg ibopamine + 40 mg furosemide
Study: 31503332
Drug: Trabectedin (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabectedin (1.5 mg/m2)
Study: 31503332
Drug: Dacarbazine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacarbazine (1 g/m2 over 20-120 minutes)
Study: 28988962
Drug: Prehospital cooling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prehospital cooling (surface ice packs, cold saline infusion, wristband reminders)
Study: 23871731
Drug: More rapid
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More rapid intravenous fluid treatment
Study: 23871731
Drug: Slower intravenous
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slower intravenous fluid treatment
Study: 8484698
Drug: Adjuvant oestrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant oestrogen treatment
Study: 21464154
Drug: Gemcitabine (1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1250 mg/m2 on days 1 and 8) and cisplatin (75 mg/m2 on day 1)
Study: 21464154
Drug: Gemcitabine (1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1250 mg/m2 on days 1 and 8), cisplatin (75 mg/m2 on day 1), and PF-3512676 (0.2 mg/kg on days 8 and 15 of each chemotherapy cycle)
Study: 19427432
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 to 40 mg/day
Study: 18210954
Drug: Topical telbermin
Normalized name: Telbermin
DrugBank: Telbermin (DB12639)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical telbermin (72 microg/cm2)
Study: 8985850
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium phosphate solution (45 mL/1.7 m2/dose)
Study: 8985850
Drug: Polyethylene glycol-based
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol-based solution (4 L/1.7 m2)
Study: 6525441
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of prednisone as a reference solution or as a tablet in a 6‐week, six‐way crossover design
Study: 6525441
Drug: Dissolution tests
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dissolution tests on five commercial tablet forms
Study: 31551229
Drug: PICC catheter
Normalized name: STATLOCK PICC
Approvals — FDA: no, EMA: no, PMDA: no
Description: PICC catheter parenteral nutrition support
Study: 29270612
Drug: Direct therapy
Normalized name: Aleve Direct Therapy TENS Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct therapy for 8 to 12 weeks
Study: 29270612
Drug: Indirect therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indirect therapy for 8 to 12 weeks
Study: 18821106
Drug: Direct therapy
Normalized name: Aleve Direct Therapy TENS Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct therapy
Study: 26818059
Drug: Titration PAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titration PAP
Study: 26818059
Drug: 6-week PAP
Normalized name: perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6-week PAP therapy
Study: 25579524
Drug: Electron beam
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electron beam therapy (16 Gy in 8 fractions)
Study: 14698542
Drug: MVP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVP regimen (Mitomycin-C 8 mg/m2 d1, Vinblastine 4 mg/m2 d 1-8, Cisplatin 100 mg/m2 d1)
Study: 14698542
Drug: MVC regimen
Normalized name: MVC-COV1901
DrugBank: MVC-COV1901 (DB15854)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVC regimen (Mitomycin-C 8 mg/m2 d1, Vinblastine 4 mg/m2 d 1-8, Carboplatin 300 mg/m2 d1)
Study: 11533519
Drug: Buflomedil (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buflomedil (600 mg once daily) for 12 months
Study: 9829381
Drug: Radioimmunoguided surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioimmunoguided surgery (RIGS) with Iodine‐125 labeled monoclonal antibodies (MoAbs) B72.3 anti‐TAG
Study: 4929367
Drug: Azathioprine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (2.5 mg/kg/day) and Prednisone (20 mg/day for adults, 0.5 mg/kg/day for children)
Study: 28114993
Drug: Telephone interview
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone interview administration of the EuroQol Health Related Quality of Life survey
Study: 28114993
Drug: Patient-completed form
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-completed form administration of the EuroQol Health Related Quality of Life survey
Study: 28114993
Drug: Both methods
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both methods of administration (telephone and patient-completed)
Study: 23225897
Drug: Intermittent preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventive treatment in infants (IPTi) with sulfadoxine‐pyrimethamine (SP) administered at 2, 3, and 9 months of age
Study: 16919749
Drug: Injected diacetylmorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injected diacetylmorphine (DAM) plus oral methadone (average DAM dosage: 274.5 mg/day; average methadone dosage: 42.6 mg/day) for 9 months
Study: 16919749
Drug: Oral methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methadone (average dosage: 105 mg/day) for 9 months
Study: 15788738
Drug: Arginine supplementation
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine supplementation (8.5 g for 4 weeks)
Study: 15788738
Drug: Isonitrogenous supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isonitrogenous supplement (control)
Study: 7790242
Drug: Daily interfraction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily interfraction interval <= 4.5 h
Study: 7790242
Drug: Daily interfraction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily interfraction interval > 4.5 h
Study: 410053
Drug: DA antagonist
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA antagonist (droperidol)
Study: 410053
Drug: ACh agonist
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACh agonist (physostigmine)
Study: 19857081
Drug: Flavocoxid 250
Normalized name: FLAVOCOXID 250MG CAP,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavocoxid 250 mg twice a day
Study: 17280748
Drug: Inactivated influenza
Normalized name: influenza, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated influenza vaccine with QS21 adjuvant
Study: 17280748
Drug: Inactivated influenza
Normalized name: influenza, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated influenza vaccine without QS21 adjuvant
Study: 11557467
Drug: Intravenous acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous acyclovir (10 mg/kg every 8 h for 14 days) followed by oral acyclovir (800 mg q6h for 42 days)
Study: 2842266
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) administered subcutaneously, 7,500 anti activated factor X Units once a day for 7 days
Study: 2842266
Drug: Calcium heparin
Normalized name: HEPARIN CALCIUM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium heparin (CH) administered subcutaneously, 5,000 International Units t.i.d. for 7 days
Study: 31808656
Drug: Intravenous opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous opioid with 1 mg/kg tramadol HCl (Group O)
Study: 30747501
Drug: Etanercept monotherapy
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept monotherapy (50 mg subcutaneous weekly)
Study: 30747501
Drug: Methotrexate monotherapy
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate monotherapy (20 mg oral weekly)
Study: 30747501
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Etanercept 50 mg subcutaneous weekly + Methotrexate 20 mg oral weekly)
Study: 30747501
Drug: Etanercept monotherapy
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept monotherapy and Combination therapy
Study: 28628970
Drug: Ankascin 568
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ankascin 568 (500 mg capsules, 2 capsules daily for 8 weeks)
Study: 23281147
Drug: BTX‐A dilution
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTX‐A dilution of 100 U in 1 ml of saline (Group A)
Study: 23281147
Drug: BTX‐A dilution
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTX‐A dilution of 100 U in 2 ml of saline (Group B)
Study: 18972731
Drug: Chinese drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese drug
Study: 12717239
Drug: mCsA (CsA
Approvals — FDA: no, EMA: no, PMDA: no
Description: mCsA (CsA dose minimization)
Study: 20093665
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of AIT and ST (COM)
Study: 16470490
Drug: Intravenous PD
Normalized name: Dianeal PD-2/2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous PD 123319 (10 mcg/minute for 5 minutes)
Study: 7690383
Drug: Midodrine 10
Normalized name: midodrine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midodrine 10 mg three times daily
Study: 7690383
Drug: Midodrine 5
Normalized name: midodrine 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midodrine 5 mg three times daily
Study: 7690383
Drug: Midodrine 2.5
Normalized name: midodrine 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midodrine 2.5 mg three times daily
Study: 3319543
Drug: All four
Normalized name: Jackson's The Original All Fours
Approvals — FDA: no, EMA: no, PMDA: no
Description: All four drugs combined
Study: 16418802
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy (ART) with observed viral load blips
Study: 16418802
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy (ART) without observed viral load blips
Study: 10856094
Drug: Docetaxel 100
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 100 mg/m² (D100)
Study: 9052337
Drug: t‐PA (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: t‐PA (0.8 mg/kg, up to a maximum dose of 80 mg)
Study: 9052337
Drug: Higher heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher heparin levels
Study: 14735048
Drug: Heparin-coated circuit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated circuit (Duraflo II)
Study: 26051095
Drug: Alpha-lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-lipoic acid (ALA) 600 mg for 12 weeks
Study: 20601692
Drug: Maternal plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal plasma viral load >100,000 copies ml⁻¹
Study: 18190710
Drug: Probiotic containing
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic containing 4 strains of live bacteria taken daily for 3 months
Study: 18190710
Drug: Identical placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical placebo taken daily for 3 months
Study: 12711121
Drug: Gemcitabine (GEM)
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine (GEM) 1000 mg/m(2), days 1, 8 and 15, every 4 weeks
Study: 12711121
Drug: Cisplatin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (100 mg/m(2), day 1) plus Vindesine (3 mg/m(2), days 1 and 15) (PV)
Study: 10921160
Drug: Zhu Yu
Normalized name: Cang zhu
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhu Yu Hua Tan Tang plus general treatment
Study: 1570392
Drug: pindolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: pindolol (80 mg over 3 days)
Study: 1570392
Drug: buspirone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: buspirone (30 mg orally)
Study: 30044439
Drug: Anthocyanines (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthocyanines (60 mg/day)
Study: 30044439
Drug: Xanthophylls (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xanthophylls (6 mg L + 2 mg Z/day)
Study: 30044439
Drug: Anthocyanines (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthocyanines (60 mg/day) + Xanthophylls (6 mg L + 2 mg Z/day)
Study: 27454919
Drug: Corticosteroid-free regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid-free regimen with Tac and MMF starting at 3 g/d, dose adjusted from day 5
Study: 27454919
Drug: Corticosteroid regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid regimen with Tac and fixed-dose MMF (2 g/d)
Study: 9246136
Drug: Prednisolone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (1 mg/kg/day orally for seven days)
Study: 8502357
Drug: Sygen‐‐monosialoganglioside 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sygen‐‐monosialoganglioside 40 mg daily
Study: 2692819
Drug: Diflunisal (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflunisal (500 mg orally, twice daily)
Study: 3329968
Drug: Piroxicam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam (20 mg orally, once daily)
Study: 31278194
Drug: Ferric citrate
Normalized name: Ferric Citrate
DrugBank: Ferric sodium citrate (DB13771)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric citrate coordination complex (two tablets per meal, 210 mg ferric iron per tablet)
Study: 24978872
Drug: Spironolactone 25
Normalized name: spironolactone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 25 mg/day (up to 100 mg/day)
Study: 17515857
Drug: Antithrombin III
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombin III (AT) agent at 1,500 U/24 h (combined group) for 3 days
Study: 17515857
Drug: Antithrombin III
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombin III (AT) agent at 500 U/8 h (divided group) for 3 days
Study: 16264051
Drug: Aspergillus fumigatus
Normalized name: Aspergillus Fumigatus
DrugBank: Aspergillus fumigatus (DB10425)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspergillus fumigatus inhalation
Study: 11850098
Drug: Acarbose, 100
Normalized name: Acarbose, 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose, 100 mg thrice daily
Study: 11850098
Drug: Glibenclamide, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide, 1 mg thrice daily
Study: 109592
Drug: 10 or
Normalized name: K-10 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 or 50 microgram doses of meningococcal group A polysaccharide vaccine
Study: 109592
Drug: 50 microgram
Normalized name: Digoxin 250 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 microgram dose of meningococcal group A polysaccharide vaccine
Study: 109592
Drug: 10 microgram
Normalized name: Estradiol 10 microgram vaginal tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 microgram dose of meningococcal group A polysaccharide vaccine
Study: 23897241
Drug: Endotracheal tube
Normalized name: Sus scrofa fallopian tube preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endotracheal tube cleaning twice daily (group B)
Study: 21827704
Drug: Latex sublingual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latex sublingual immunotherapy
Study: 9582586
Drug: Ciprofloxacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (100 mg)
Study: 30626285
Drug: Transdermal glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal glyceryl trinitrate (GTN) for 7 days
Study: 25906949
Drug: Boron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boron supplementation (10 mg/day)
Study: 20335550
Drug: 1 capsule/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule/day of omega-3 PUFA supplement providing 0.84 g DHA + EPA
Study: 20335550
Drug: 3 capsules/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 capsules/day of omega-3 PUFA supplement providing 2.52 g DHA + EPA
Study: 20335550
Drug: 6 capsules/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 capsules/day of omega-3 PUFA supplement providing 5.04 g DHA + EPA
Study: 20335550
Drug: 9 capsules/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 capsules/day of omega-3 PUFA supplement providing 7.56 g DHA + EPA
Study: 16131771
Drug: Intravenous diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diazepam (without prior i.v. access)
Study: 16131771
Drug: Intravenous diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diazepam (with prior i.v. access)
Study: 10503678
Drug: Iron treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron treatment for pupils with s-ferritin <15 microg/l, duration of 3 months
Study: 8607723
Drug: Active drug
Normalized name: Capillary active drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drug treatment (chlorthalidone 15 mg/d, acebutolol hydrochloride 400 mg/d, doxazosin mesylate 2 mg/d, amlodipine besylate 5 mg/d, enalapril maleate 5 mg/d)
Study: 8607723
Drug: Active drug
Normalized name: Capillary active drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drug treatment (all active drugs combined)
Study: 1953524
Drug: Interferon alpha
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha 2b (3 million units subcutaneously thrice weekly for 24 weeks)
Study: 1953524
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (observed without treatment for 12 months)
Study: 25163906
Drug: Cilengitide 2000
Normalized name: Cilengitide
DrugBank: Cilengitide (DB11890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilengitide 2000 mg intravenously twice weekly combined with temozolomide chemoradiotherapy
Study: 19648823
Drug: Raltegravir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir (400 mg twice a day after 48 weeks)
Study: 19648823
Drug: Efavirenz (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efavirenz (600 mg every day)
Study: 8800392
Drug: Naltrexone (NTX),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (NTX), 50 mg/day, po
Study: 1731285
Drug: Transdermal E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal E2 0.1 mg for 24.5 days of each 28‐day cycle for 96 weeks
Study: 1731285
Drug: Transdermal E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal E2 0.1 mg plus 10 mg of medroxyprogesterone acetate from days 13‐25 of each cycle
Study: 31003690
Drug: Topical sesame
Normalized name: Sesame Oil
DrugBank: Sesame oil (DB11172)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical sesame oil with massage (10 drops, twice a day for 7 days)
Study: 24988438
Drug: RAL 800
Normalized name: ABSTRAL 800mcg Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAL 800 mg by chewing
Study: 24988438
Drug: RAL 400
Normalized name: Sectral 400mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAL 400 mg by swallowing
Study: 19865065
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 terclatrate (QTer) 200 mg orally once daily for 7 days before noise exposure
Study: 9158165
Drug: Clonidine (transdermal,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (transdermal, given for 5 days)